Literature DB >> 2944670

Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography.

G H Dahlen, J R Guyton, M Attar, J A Farmer, J A Kautz, A M Gotto.   

Abstract

In a study of 307 white patients who underwent coronary angiography, the relationship of coronary artery disease (CAD) to plasma levels of lipoprotein Lp(a) and other lipid-lipoprotein variables was examined. Lp(a) resembles low-density lipoprotein (LDL) in several ways, but can be distinguished and quantified by electroimmunoassay. CAD was rated as present or absent and was also represented by a quantitative lesion score derived from estimates of stenosis in four major coronary vessels. Coronary lesion scores significantly correlated with Lp(a), total cholesterol, triglycerides, LDL cholesterol, and high-density lipoprotein (HDL) cholesterol levels by univariate statistical analysis. By multivariate analysis levels of Lp(a) were associated significantly and independently with the presence of CAD (p less than .02), and tended to correlate with lesion scores (p = .06). Among subgroups Lp(a) level was associated with CAD in women of all ages and in men 55 years old or younger. An apparent threshold for coronary risk occurred at Lp(a) lipoprotein mass concentrations of 30 to 40 mg/dl, corresponding to Lp(a) cholesterol concentrations of approximately 10 to 13 mg/dl. Plasma Lp(a) in white patients appears to be a major coronary risk factor with an importance approaching that of the level of LDL or HDL cholesterol.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2944670     DOI: 10.1161/01.cir.74.4.758

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  96 in total

1.  An application of apo(a) isoforms for the clinical assessment of Lp(a).

Authors:  S Takayama; Y Yasumuro; J h Kim; M Ishikawa; D Tsujino; S Matsuo; Y Harada; S Sugii
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

2.  Hypercholesterolemia and Dyslipidemia.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-04

3.  Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin.

Authors:  L Slunga; O Johnson; G H Dahlén
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 4.  Lipoprotein(a): an elusive cardiovascular risk factor.

Authors:  Lars Berglund; Rajasekhar Ramakrishnan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-09-02       Impact factor: 8.311

5.  Lipid profile, haemostatic variables and angiographically-defined coronary artery disease: a cross-sectional study in an Irish population.

Authors:  J Galvin; M Codd; S Leavy; D Sugrue
Journal:  Ir J Med Sci       Date:  1996 Apr-Jun       Impact factor: 1.568

Review 6.  Genetic basis of lipoprotein disorders.

Authors:  J L Breslow
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

7.  Mutagenesis of the human apolipoprotein B gene in a yeast artificial chromosome reveals the site of attachment for apolipoprotein(a).

Authors:  S P McCormick; J K Ng; S Taylor; L M Flynn; R E Hammer; S G Young
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

Review 8.  Recent advances in lipoprotein and atherosclerosis research at Baylor College of Medicine. Apolipoprotein B, lipoprotein[a], and transplantation arteriopathy.

Authors:  C M Ballantyne; L Chan; J Guevara; J D Morrisett; M P Mims; A M Gotto
Journal:  Tex Heart Inst J       Date:  1994

9.  Like father like son? Sons of patients of European or Indian origin with coronary artery disease reflect their parents' risk factor patterns.

Authors:  N Shaukat; D P de Bono; D R Jones
Journal:  Br Heart J       Date:  1995-09

10.  Limited discriminant value of lipoprotein AI, lipoprotein Lp(a) and other lipoprotein particles in patients with and without early onset ischaemic heart disease.

Authors:  D T Vallance; H A Staunton; A F Winder
Journal:  J Clin Pathol       Date:  1995-01       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.